Edition:
United States

Morphosys AG (MORG.DE)

MORG.DE on Xetra

38.98EUR
4:07am EDT
Change (% chg)

€-0.16 (-0.41%)
Prev Close
€39.14
Open
€39.28
Day's High
€39.28
Day's Low
€38.78
Volume
4,040
Avg. Vol
135,987
52-wk High
€75.13
52-wk Low
€32.90

MORG.DE

Chart for MORG.DE

About

MorphoSys AG (MorphoSys) develops and commercializes antibodies for therapeutic applications. The Company's operating segments include Proprietary Development and Partnered Discovery. The Company develops new treatments for patients suffering from serious diseases. The Company has a total of approximately 100 individual... (more)

Overall

Beta: 0.47
Market Cap(Mil.): €1,038.69
Shares Outstanding(Mil.): 26.54
Dividend: --
Yield (%): --

Financials

  MORG.DE Industry Sector
P/E (TTM): -- 39.80 37.05
EPS (TTM): -1.28 -- --
ROI: -8.75 -5.86 14.35
ROE: -8.92 -4.70 15.56

BRIEF-Morphosys shares up 4.4 pct after Novartis milestone payment

* Shares rise 4.4 percent at open following Novartis milestone payment for clinical trial Source text for Eikon: Further company coverage:

Jul 04 2016

BRIEF-Morphosys gets Novartis milestone payment for phase 1 trial

* Morphosys receives clinical milestone for start of phase 1 trial in prevention of thrombosis with novel antibody

Jul 04 2016

BRIEF-Morphosys, MD Anderson to cooperate on oncology therapeutics

* Morphosys and md anderson cancer center join forces for development of novel oncology therapeutics

May 24 2016

BRIEF-Morphosys posts smaller than expected Q1 EBIT loss

* Says group revenue in Q1 of 2016 reached 12.1 million euros ($13.96 million) (Q1/2015: 70.4 million euros)

May 03 2016

BRIEF-Morphosys says licensing partner GSK starts phase 2 osteoarthritis study

* Says licensing partner gsk starts phase 2 study with gsk3196165 (mor103) in hand osteoarthritis For the statement Further company coverage:

Apr 18 2016

BRIEF-Galapagos and Morphosys initiate phase 1 study in joint antibody program MOR106

* Galapagos and Morphosys initiate phase 1 study in joint antibody program MOR106

Apr 07 2016

BRIEF-Morphosys, Galapagos initiate Phase 1 study in joint antibody program MOR106

* Morphosys and galapagos initiate phase 1 study in joint antibody program mor106

Apr 07 2016

BRIEF-Morphosys initiates Phase 2 trial of MOR208 and Lenalidomide

* Morphosys initiates Phase 2 combination trial of MOR208 and Lenalidomide in patients with relapsed or refractory diffuse large b cell lymphoma (DLBCL) Source text for Eikon: Further company coverage:

Apr 06 2016

BRIEF-Morphosys AG sees 2016 EBIT loss of 58-68 million euros

* product pipeline further expanded in 2015 to 103 programs

Mar 02 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00
Provider : Wright Reports
$75.00
Provider : Sadif Analytics Prime
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.